Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H | O95180 | 16/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8201808 | 0.92 | CACNA1H (0.54) | CACNA1HCYP3A4CYP2C9CYP2C19LMNA | |
| SCHEMBL8202771 | 0.91 | CACNA1H (0.52) | CACNA1HCYP3A4CYP2C9CYP2C19LMNA | |
| SCHEMBL8202768 | 0.90 | CACNA1H (0.52) | CACNA1HCYP3A4CYP2C9CYP2C19LMNA | |
| SCHEMBL8210221 | 0.86 | ALDH1A1 (0.53) | CACNA1HCYP3A4CYP2C9CYP2C19LMNA | |
| SCHEMBL8212363 | 0.86 | CACNA1H (0.47) | CACNA1HCYP3A4CYP2C9CYP2C19LMNA | |
| SCHEMBL8214603 | 0.85 | CYP3A4 (0.48) | CACNA1HCYP3A4CYP2C9CYP2C19LMNA | |
| SCHEMBL8210233 | 0.85 | CACNA1H (0.47) | CACNA1HCYP3A4CYP2C9CYP2C19LMNA | |
| SCHEMBL12877005 | 0.78 | CACNA1H (1.00) | CACNA1H | |
| SCHEMBL8213097 | 0.78 | CACNA1H (1.00) | CACNA1H | |
| SCHEMBL8202226 | 0.77 | CACNA1H (1.00) | CACNA1H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7884080-B2 | Administering an azetidinone compound for treating a disorder of lipid metabolism, pain, diabetes, a vascular condition, demyelination or nonalcoholic fatty liver disease; T-type calcium channel blocking agent, an antagonist of TRPV1, an agonist of TRPV1, of GPR119, antagonist of NPCL1 | SCHERING PLOUGH CORPORATION (US) | 2011-02-08 | — | — | US | disclosed |
| US-7884080-B2 | Administering an azetidinone compound for treating a disorder of lipid metabolism, pain, diabetes, a vascular condition, demyelination or nonalcoholic fatty liver disease; T-type calcium channel blocking agent, an antagonist of TRPV1, an agonist of TRPV1, of GPR119, antagonist of NPCL1 | SCHERING PLOUGH CORPORATION (US) | 2011-02-08 | — | — | US | disclosed |
| US-20080076751-A1 | Azetidinone Derivatives and Methods of Use Thereof | MERCK SHARP & DOHME CORP. | 2008-03-27 | — | — | US | disclosed |
| US-20080076751-A1 | Azetidinone Derivatives and Methods of Use Thereof | MERCK SHARP & DOHME CORP. | 2008-03-27 | — | — | US | disclosed |
| WO-2008033464-A2 | AZETIDINONE DERIVATIVES FOR THE TREATMENT OF DISORDERS OF THE LIPID METABOLISM | SCHERING CORPORATION (US) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076751-A1 | Azetidinone Derivatives and Methods of Use Thereof | LIPC, ZDHHC20, FABP1 | CACNA1H 2929/4885CYP3A4 343/4885CYP2C9 558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.